What is Oppenheimer's price target for DYN?

Oppenheimer's latest stated price target for Dyne Therapeutics Inc. (DYN) is $15, from its action on Oct 28, 2026.

What is Oppenheimer's rating on DYN?

Oppenheimer rates DYN Perform, a neutral rating, as of Oct 28, 2026.

When did Oppenheimer last change its view on DYN?

On Oct 28, 2026, Oppenheimer downgrades to Perform from Outperform, price target $15.

Oppenheimer DYN price target and rating history

Dyne Therapeutics Inc. (DYN) · Health Care

Oppenheimer rates Dyne Therapeutics Inc. (DYN) Perform with a $15 price target, as of its latest action on Oct 28, 2026. It has published 5 rating actions on DYN since February 2023, including 1 upgrade and 2 downgrades.

Current rating: Perform
Price target: $15
Median target, all firms: Too few
Actions on DYN: 5

Oppenheimer price target on DYN

Oppenheimer price target on DYN, each point a stated target, February 2023 to October 2026.

Every Oppenheimer rating on DYN

Oct 28, 2026
DowngradeOppenheimer downgrades to Perform from Outperform, price target $15
Dec 10, 2025
UpgradeOppenheimer upgrades to Outperform from Perform, price target $40
Oct 10, 2025
DowngradeOppenheimer downgrades to Perform from Outperform
Jun 2, 2025
ResumeOppenheimer resumes coverage at Outperform, price target $34
Feb 15, 2023
InitiateOppenheimer starts coverage at Outperform, price target $34

How other firms rate DYN

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Oppenheimer	Perform	$15	Oct 28, 2026
Cantor Fitzgerald	Overweight		Jul 23, 2026
TD Cowen	Buy		Jun 26, 2026

Questions about Oppenheimer and DYN

What is Oppenheimer's price target for DYN?: Oppenheimer's latest stated price target for Dyne Therapeutics Inc. (DYN) is $15, from its action on Oct 28, 2026.
What is Oppenheimer's rating on DYN?: Oppenheimer rates DYN Perform, a neutral rating, as of Oct 28, 2026.
When did Oppenheimer last change its view on DYN?: On Oct 28, 2026, Oppenheimer downgrades to Perform from Outperform, price target $15.

More DYN rating histories

Raymond James4

All Oppenheimer ratings DYN news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.